Shares of Becton Dickinson & Co. dropped 3.1% in morning trade Thursday, after the medical technology company topped fiscal second-quarter profit expectations, but slashed its full-year outlook, citing "recent regulatory and market pressures related to paclitaxel-coated devices." The net loss for the latest quarter narrowed to $18 million, or 7 cents a share, from $50 million, or 19 cents a share, in the same period a year ago. Adjusted EPS, which excludes non-recurring items, fell 2.3% to $2.59, but topped the FactSet consensus of $2.58. Revenue declined 0.6% to $4.195 billion, just shy of the FactSet consensus of $4.238 billion. For fiscal 2019, the company cut its adjusted EPS guidance range to $11.65 to $11.75 from $12.05 to $12.15. The company also lowered its revenue growth outlook to 8.0% to 9.0% from 8.5% to 9.5%, citing an estimated additional negative impact from currency moves. The stock has now slipped 0.1% year to date, while the SPDR Health Care Select Sector ETF has gained 2.3% and the S&P 500 has tacked on 13.8%.